Advanced melanoma remains one of the greatest challenges in modern oncology. The advent of immune checkpoint inhibitors (ICI), such as anti–PD-1 agents (pembrolizumab, nivolumab), revolutionized survival outcomes in this disease, but this revolution brought with it a clinical paradox: while a fraction of patients achieves complete and sustained remissions, a significant majority develops resistance. It is this population—the anti–PD-1-refractory patients—for which the therapeutic arsenal remains limited, poorly defined, and clinically insufficient. This is where the SPOTLIGHT-203 study becomes especially relevant—a multicenter phase II trial evaluating the combination of BO-112, an intratumoral immunostimulant, with pembrolizumab in patients with advanced refractory melanoma.
To understand the innovation behind BO-112, it is essential to briefly review the immunological mechanisms of tumor immune evasion. Tumor cells, especially in advanced stages, modify their immediate surroundings—the tumor microenvironment (TME)—through the secretion of immunosuppressive cytokines, the exclusion of cytotoxic T cells, and the loss of antigen presentation. The result is the conversion of the tumor into an “immune-cold” entity, immunologically invisible. ICIs such as pembrolizumab work by blocking the interaction between PD-1 on T cells and its ligand PD-L1 on tumor or immunosuppressive cells, thereby reactivating exhausted T cells. However, in the absence of innate immune activation, antigen presentation, or lymphocyte infiltration, this blockade is ineffective.
BO-112, a nanoparticle composed of double-stranded RNA (poly I:C) complexed with polyethyleneimine, mimics an intracellular viral infection by activating intracellular viral RNA sensors such as TLR3, RIG-I, and MDA5. This activation triggers a potent type I interferon inflammatory response, with expression of ISG (Interferon-Stimulated Genes), tumor cell apoptosis, dendritic cell maturation, and migration of CD8+ T cells to the TME. In animal models, even in the absence of a functional interferon pathway, BO-112 has reversed anti–PD-1 resistance. This mechanism turns a “cold” tumor into a “hot” one—a fundamental condition for pembrolizumab to be effective.
In SPOTLIGHT-203, 42 patients with advanced melanoma who had progressed under anti–PD-1 therapy—even in adjuvant settings—were selected. Patients received intratumoral BO-112 injections in up to eight lesions, complemented with pembrolizumab infusions every three weeks. The study design focused on patients with documented progression according to RECIST 1.1, thus avoiding confusion with pseudoprogressive or delayed responses. This level of rigor reinforces the reliability of the results obtained.
The objective response rate (ORR) in the evaluable population was 25%, well above the statistical significance threshold (20%). Complete responses (10%) and partial responses (15%) were all confirmed by independent radiological review. Even more significant was the durability of these responses: at 12 months, 85.7% of responders maintained clinical benefit, and the median duration of response was not reached. Median progression-free survival (PFS) was 3.7 months, consistent with other studies in this population. However, the truly disruptive finding was the 54% overall survival at 24 months, a remarkable figure in a refractory context.
From an immunological perspective, sequential biopsies demonstrated robust changes in the tumor microenvironment: increased CD8+ infiltration, elevated expression of T cell activation genes, and tumor apoptosis. These findings validate the theoretical model of immune conversion induced by BO-112. Furthermore, subgroup analyses revealed that patients with BRAF or NRAS mutations and without MYC amplification showed greater clinical benefit, suggesting potential genomic biomarkers predictive of response to this strategy.
When comparing these results with other available strategies, the combination of BO-112 plus pembrolizumab is competitively positioned. For example, tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel, demonstrated a 36% ORR and 4.1-month PFS, but with high logistical complexity and elevated costs. The ipilimumab plus nivolumab combination, although effective in some patients, carries grade ≥3 toxicity in over 50% of cases. In contrast, BO-112 showed grade ≥3 treatment-related toxicity in only 9.5%, with mostly mild and transient adverse events such as fever, fatigue, or gastrointestinal discomfort.
Figure 1. Intratumoral BO-112 activates innate immunity and converts a “cold” tumor into a “hot” one. When combined with pembrolizumab, it enhances T cell infiltration and immune response, promoting tumor control even in non-injected lesions.
One fascinating aspect was the observation of responses even in non-injected lesions, indicating a possible immune-mediated abscopal effect—that is, a systemic immune response generated from a local intervention. This phenomenon, though previously described with radiotherapy or oncolytic viruses, is rarely confirmed with non-viral compounds like BO-112. Its non-infectious profile, combined with stability and ease of administration, makes it particularly attractive compared to agents like T-VEC or RP-1, which require more complex biological infrastructure.
However, not all outcomes were uniform. Patients with acral melanoma or very elevated LDH levels did not show clear benefits, indicating that certain clinical and biological characteristics may limit the efficacy of the approach. Conversely, patients with mucosal melanoma, typically considered poor prognosis, showed encouraging responses, warranting further targeted investigation in this population.
In conclusion, the SPOTLIGHT-203 study not only met its primary objective but also proposes an entirely new immunotherapeutic paradigm: the combination of local immune activation with systemic checkpoint inhibition to overcome acquired resistance. BO-112 positions itself as a modulator of the tumor microenvironment—potentially essential to restoring the efficacy of anti–PD-1 therapies in settings where they have failed. The next logical step will be evaluation in larger randomized trials, including more diverse populations and integrated molecular analyses. If these findings are confirmed, we may be witnessing the emergence of a new generation of combination immunotherapies, capable not only of attacking the tumor but of retraining the immune system to recognize and eradicate it.
Main Reference:
Iván Márquez-Rodas et al. BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. JCO 0, JCO-24-02595
DOI:10.1200/JCO-24-02595 (https://ascopubs.org/doi/10.1200/JCO-24-02595)
Other References:
Long, G. V., Carlino, M. S., McNeil, C., Ribas, A., Gaudy-Marqueste, C., Schachter, J., Nyakas, M., Kee, D., Petrella, T. M., Blaustein, A., Lotem, M., Arance, A. M., Daud, A. I., Hamid, O., Larkin, J., Yao, L., Singh, R., Lal, R., & Robert, C. (2024). Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of oncology : official journal of the European Society for Medical Oncology, 35(12), 1191–1199. https://doi.org/10.1016/j.annonc.2024.08.2330
Wolchok, J. D., Chiarion-Sileni, V., Rutkowski, P., Cowey, C. L., Schadendorf, D., Wagstaff, J., Queirolo, P., Dummer, R., Butler, M. O., Hill, A. G., Postow, M. A., Gaudy-Marqueste, C., Medina, T., Lao, C. D., Walker, J., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., … CheckMate 067 Investigators (2025). Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine, 392(1), 11–22. https://doi.org/10.1056/NEJMoa2407417
Long, G. V., Stephen Hodi, F., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., Janoski De Menezes, J., Dalle, S., Arance, A., Grob, J. J., Keidel, S., Shaikh, A., Sobiesk, A. M., Dolfi, S., & Tawbi, H. A. (2023). Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM evidence, 2(4), EVIDoa2200239. https://doi.org/10.1056/EVIDoa2200239
